134 related articles for article (PubMed ID: 38890488)
1. Analysis of 10,478 cancer genomes identifies candidate driver genes and opportunities for precision oncology.
Kinnersley B; Sud A; Everall A; Cornish AJ; Chubb D; Culliford R; Gruber AJ; Lärkeryd A; Mitsopoulos C; Wedge D; Houlston R
Nat Genet; 2024 Jun; ():. PubMed ID: 38890488
[TBL] [Abstract][Full Text] [Related]
2. Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels.
Ramarao-Milne P; Kondrashova O; Patch AM; Nones K; Koufariotis LT; Newell F; Addala V; Lakis V; Holmes O; Leonard C; Wood S; Xu Q; Mukhopadhyay P; Naeini MM; Steinfort D; Williamson JP; Bint M; Pahoff C; Nguyen PT; Twaddell S; Arnold D; Grainge C; Basirzadeh F; Fielding D; Dalley AJ; Chittoory H; Simpson PT; Aoude LG; Bonazzi VF; Patel K; Barbour AP; Fennell DA; Robinson BW; Creaney J; Hollway G; Pearson JV; Waddell N
ESMO Open; 2022 Aug; 7(4):100540. PubMed ID: 35849877
[TBL] [Abstract][Full Text] [Related]
3. Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer.
Xu C; Nikolova O; Basom RS; Mitchell RM; Shaw R; Moser RD; Park H; Gurley KE; Kao MC; Green CL; Schaub FX; Diaz RL; Swan HA; Jang IS; Guinney J; Gadi VK; Margolin AA; Grandori C; Kemp CJ; Méndez E
Clin Cancer Res; 2018 Jun; 24(12):2828-2843. PubMed ID: 29599409
[No Abstract] [Full Text] [Related]
4. Insights for precision oncology from the integration of genomic and clinical data of 13,880 tumors from the 100,000 Genomes Cancer Programme.
Sosinsky A; Ambrose J; Cross W; Turnbull C; Henderson S; Jones L; Hamblin A; Arumugam P; Chan G; Chubb D; Noyvert B; Mitchell J; Walker S; Bowman K; Pasko D; Buongermino Pereira M; Volkova N; Rueda-Martin A; Perez-Gil D; Lopez J; Pullinger J; Siddiq A; Zainy T; Choudhury T; Yavorska O; Fowler T; Bentley D; Kingsley C; Hing S; Deans Z; Rendon A; Hill S; Caulfield M; Murugaesu N
Nat Med; 2024 Jan; 30(1):279-289. PubMed ID: 38200255
[TBL] [Abstract][Full Text] [Related]
5. Single whole genome sequencing analysis blazes the trail for precision medicine.
Napoli GC; Chau CH; Figg WD
Cancer Biol Ther; 2022 Dec; 23(1):134-135. PubMed ID: 35129071
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
[TBL] [Abstract][Full Text] [Related]
7. Decoding human cancer with whole genome sequencing: a review of PCAWG Project studies published in February 2020.
Giunta S
Cancer Metastasis Rev; 2021 Sep; 40(3):909-924. PubMed ID: 34097189
[TBL] [Abstract][Full Text] [Related]
8. Whole genome sequencing analysis for cancer genomics and precision medicine.
Nakagawa H; Fujita M
Cancer Sci; 2018 Mar; 109(3):513-522. PubMed ID: 29345757
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Characterization of Cancer Driver Genes and Mutations.
Bailey MH; Tokheim C; Porta-Pardo E; Sengupta S; Bertrand D; Weerasinghe A; Colaprico A; Wendl MC; Kim J; Reardon B; Ng PK; Jeong KJ; Cao S; Wang Z; Gao J; Gao Q; Wang F; Liu EM; Mularoni L; Rubio-Perez C; Nagarajan N; Cortés-Ciriano I; Zhou DC; Liang WW; Hess JM; Yellapantula VD; Tamborero D; Gonzalez-Perez A; Suphavilai C; Ko JY; Khurana E; Park PJ; Van Allen EM; Liang H; ; ; Lawrence MS; Godzik A; Lopez-Bigas N; Stuart J; Wheeler D; Getz G; Chen K; Lazar AJ; Mills GB; Karchin R; Ding L
Cell; 2018 Apr; 173(2):371-385.e18. PubMed ID: 29625053
[TBL] [Abstract][Full Text] [Related]
10. Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations.
Wardell CP; Fujita M; Yamada T; Simbolo M; Fassan M; Karlic R; Polak P; Kim J; Hatanaka Y; Maejima K; Lawlor RT; Nakanishi Y; Mitsuhashi T; Fujimoto A; Furuta M; Ruzzenente A; Conci S; Oosawa A; Sasaki-Oku A; Nakano K; Tanaka H; Yamamoto Y; Michiaki K; Kawakami Y; Aikata H; Ueno M; Hayami S; Gotoh K; Ariizumi SI; Yamamoto M; Yamaue H; Chayama K; Miyano S; Getz G; Scarpa A; Hirano S; Nakamura T; Nakagawa H
J Hepatol; 2018 May; 68(5):959-969. PubMed ID: 29360550
[TBL] [Abstract][Full Text] [Related]
11. Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.
Wedge DC; Gundem G; Mitchell T; Woodcock DJ; Martincorena I; Ghori M; Zamora J; Butler A; Whitaker H; Kote-Jarai Z; Alexandrov LB; Van Loo P; Massie CE; Dentro S; Warren AY; Verrill C; Berney DM; Dennis N; Merson S; Hawkins S; Howat W; Lu YJ; Lambert A; Kay J; Kremeyer B; Karaszi K; Luxton H; Camacho N; Marsden L; Edwards S; Matthews L; Bo V; Leongamornlert D; McLaren S; Ng A; Yu Y; Zhang H; Dadaev T; Thomas S; Easton DF; Ahmed M; Bancroft E; Fisher C; Livni N; Nicol D; Tavaré S; Gill P; Greenman C; Khoo V; Van As N; Kumar P; Ogden C; Cahill D; Thompson A; Mayer E; Rowe E; Dudderidge T; Gnanapragasam V; Shah NC; Raine K; Jones D; Menzies A; Stebbings L; Teague J; Hazell S; Corbishley C; ; de Bono J; Attard G; Isaacs W; Visakorpi T; Fraser M; Boutros PC; Bristow RG; Workman P; Sander C; ; Hamdy FC; Futreal A; McDermott U; Al-Lazikani B; Lynch AG; Bova GS; Foster CS; Brewer DS; Neal DE; Cooper CS; Eeles RA
Nat Genet; 2018 May; 50(5):682-692. PubMed ID: 29662167
[TBL] [Abstract][Full Text] [Related]
12. Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine.
Nagahashi M; Wakai T; Shimada Y; Ichikawa H; Kameyama H; Kobayashi T; Sakata J; Yagi R; Sato N; Kitagawa Y; Uetake H; Yoshida K; Oki E; Kudo SE; Izutsu H; Kodama K; Nakada M; Tse J; Russell M; Heyer J; Powers W; Sun R; Ring JE; Takabe K; Protopopov A; Ling Y; Okuda S; Lyle S
Genome Med; 2016 Dec; 8(1):136. PubMed ID: 28007036
[TBL] [Abstract][Full Text] [Related]
13. Landscape of driver gene events, biomarkers, and druggable targets identified by whole-genome sequencing of glioblastomas.
van de Geer WS; Hoogstrate Y; Draaisma K; Robe PA; Bins S; Mathijssen RHJ; French P; van de Werken HJG; de Vos FYF
Neurooncol Adv; 2022; 4(1):vdab177. PubMed ID: 35047820
[TBL] [Abstract][Full Text] [Related]
14. Sarcoma and the 100,000 Genomes Project: our experience and changes to practice.
Prendergast SC; Strobl AC; Cross W; Pillay N; Strauss SJ; Ye H; Lindsay D; Tirabosco R; Chalker J; Mahamdallie SS; Sosinsky A; ; ; Flanagan AM; Amary F
J Pathol Clin Res; 2020 Oct; 6(4):297-307. PubMed ID: 32573957
[TBL] [Abstract][Full Text] [Related]
15. Combined burden and functional impact tests for cancer driver discovery using DriverPower.
Shuai S; ; Gallinger S; Stein LD;
Nat Commun; 2020 Feb; 11(1):734. PubMed ID: 32024818
[TBL] [Abstract][Full Text] [Related]
16. Comparison of different functional prediction scores using a gene-based permutation model for identifying cancer driver genes.
Nono AD; Chen K; Liu X
BMC Med Genomics; 2019 Jan; 12(Suppl 1):22. PubMed ID: 30704472
[TBL] [Abstract][Full Text] [Related]
17. Molecular tests and target therapies in oncology: recommendations from the Italian workshop.
Pinto C; Biffoni M; Popoli P; Marchetti A; Marchetti P; Martini N; Normanno N
Future Oncol; 2021 Sep; 17(26):3529-3539. PubMed ID: 34254524
[TBL] [Abstract][Full Text] [Related]
18. Individualized network-based drug repositioning infrastructure for precision oncology in the panomics era.
Cheng F; Hong H; Yang S; Wei Y
Brief Bioinform; 2017 Jul; 18(4):682-697. PubMed ID: 27296652
[TBL] [Abstract][Full Text] [Related]
19. Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes.
Wilmott JS; Field MA; Johansson PA; Kakavand H; Shang P; De Paoli-Iseppi R; Vilain RE; Pupo GM; Tembe V; Jakrot V; Shang CA; Cebon J; Shackleton M; Fitzgerald A; Thompson JF; Hayward NK; Mann GJ; Scolyer RA
Pathology; 2015 Dec; 47(7):683-93. PubMed ID: 26517638
[TBL] [Abstract][Full Text] [Related]
20. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
